• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Thursday, November 19, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Distinct proteomic patterns link hepatitis B treatments to HBsAg decline

by
November 10, 2026
in Health
Reading Time: 3 mins read
0
Distinct proteomic patterns link hepatitis B treatments to HBsAg decline

Distinct proteomic patterns link hepatitis B treatments to HBsAg decline

Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Researchers have identified distinct longitudinal plasma proteomic trajectories associated with two different immunomodulatory therapies for chronic hepatitis B, suggesting that specific protein changes may correlate with favorable treatment responses. The study, published in Frontiers in Cellular and Infection Microbiology, examined how pegylated interferon-alpha (PEG-IFNα) and PD-1 blockade alter the circulating inflammatory proteome in patients whose viral replication is already suppressed by nucleos(t)ide analogues. By profiling plasma samples over a 24-week period, the team found that while both therapies induce immune remodeling, the breadth and timing of these changes differ significantly between the two treatment modalities.

The investigation focused on 25 patients with chronic hepatitis B who were receiving either PD-1 blockade or PEG-IFNα therapy. The cohort was divided into two groups: ten patients received PD-1 blockade, and fifteen patients received PEG-IFNα. All participants were nucleos(t)ide analogue-suppressed. Plasma samples were collected at three distinct time points: baseline, week 12, and week 24, providing a longitudinal view of how the proteome evolved in response to each therapy.

The researchers performed longitudinal plasma proteomic profiling using the Olink Target 96 Inflammation panel. Of the proteins measured, seventy-seven passed the quality-control criteria and were included in the final analysis. The study employed linear mixed-effects models to analyze longitudinal protein changes.

The primary results indicated that PEG-IFNα induced substantially broader longitudinal proteomic remodeling compared to PD-1 blockade. Most of the significant protein changes in the PEG-IFNα group occurred within the first 12 weeks of treatment. In contrast, the PD-1 blockade group showed a more limited range of proteomic shifts. Treatment-by-time analyses revealed distinct trajectories for the two therapies, highlighting differential changes in several key inflammatory markers, including IL-18R1, TNF, CX3CL1, CXCL9, and CXCL10.

The researchers also evaluated the association between these proteomic changes and clinical response, defined as a decline in hepatitis B surface antigen (HBsAg) of at least one log10 IU/mL by week 24. Using responder–non-responder comparisons and Spearman’s rank correlation, the team identified treatment-specific patterns linked to this favorable decline. In the PD-1 blockade cohort, IL-10 emerged as the leading exploratory signal associated with HBsAg decline. In the PEG-IFNα cohort, IL-12B, CDCP1, and FGF-21 were more prominent in the response-associated analyses.

However, the study emphasizes that these response-related associations did not remain significant after false discovery rate correction. Consequently, the authors classified these findings as exploratory rather than definitive biomarkers.

The findings support the potential value of longitudinal proteomics for mechanistic and biomarker studies of HBV functional-cure strategies. By demonstrating that favorable HBsAg decline is accompanied by treatment-specific rather than universal proteomic signatures, the research highlights the potential value of tracking dynamic immune changes over time.

Limitations of the study include the relatively small sample size, with only ten patients in the PD-1 blockade group and fifteen in the PEG-IFNα group.

Subject of Research: Longitudinal plasma proteomic profiling of PD-1 blockade and PEG-IFNα therapy in chronic hepatitis B

Article Title: Distinct plasma proteomic trajectories during PD-1 blockade and PEG-IFNα therapy are associated with HBsAg response in chronic hepatitis B

Article References: Wang, H., Li, Y., Li, X., Zhang, X., Wang, Q., Liu, S., Yang, S., Zhang, X., Qiao, X., Dang, S., Wang, F.-S., & Fu, J. (2026). Distinct plasma proteomic trajectories during PD-1 blockade and PEG-IFNα therapy are associated with HBsAg response in chronic hepatitis B. Frontiers in Cellular and Infection Microbiology, 16, Article 1996565. https://doi.org/10.3389/fcimb.2026.1996565

Image Credits: AI Generated

DOI: 10.3389/fcimb.2026.1996565

Keywords: chronic hepatitis B, plasma proteomics, PD-1 blockade, PEG-IFNα, HBsAg decline, inflammatory proteins, immunomodulation, biomarkers, Olink panel, longitudinal study, Distinct, plasma

News Source: Kristina Jarvis. (November 10, 2026). Distinct proteomic patterns link hepatitis B treatments to HBsAg decline. Scienmag.

Tags: biomarkerschronic hepatitis BDistinctHBsAg declineimmunomodulationinflammatory proteinslongitudinal studyOlink panelPD-1 blockadePEG-IFNαplasmaplasma proteomics
Share12Tweet7Share2ShareShareShare1

Related Posts

Deprescribing Guideline Implementation Relies on Internal Clinic Champions and Systems

Deprescribing Guideline Implementation Relies on Internal Clinic Champions and Systems

November 19, 2026
Bimaxillary Surgery Corrects Lip Canting More Predictably Than Eye Tilt

Bimaxillary Surgery Corrects Lip Canting More Predictably Than Eye Tilt

November 19, 2026

Systematic Review Maps Diverse Lateralized and Unilateral Manifestations of Lupus

November 19, 2026

Pediatric Extended Reality Motor Training Relies Largely on Customized Non-Immersive Tools

November 19, 2026

POPULAR NEWS

  • Somatic Symptom Burden in Oral Health Clinic Patients Shifted Modestly Across Pandemic

    Somatic Symptom Burden in Oral Health Clinic Patients Shifted Modestly Across Pandemic

    29 shares
    Share 12 Tweet 7
  • Multicenter ICU Study Identifies Nurse Knowledge Gaps in Pneumonia Prevention

    29 shares
    Share 12 Tweet 7
  • Study Finds One-Third of Ethiopian Neuropsychiatric Patients Exhibit Harmful Alcohol Use

    29 shares
    Share 12 Tweet 7
  • Low-Dose Epidural Analgesia Modestly Lengthens Labor Stages in Low-Risk Women

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Pneumonia Model Shows Public Awareness and Rapid Treatment Can Eliminate Transmission

Deprescribing Guideline Implementation Relies on Internal Clinic Champions and Systems

High-Altitude Hypoxia Suppresses Varroa Mite Reproduction in Honey Bee Colonies

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 89 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.